RE:RE:RE:RE:RE:The competition had been launched! Where's Aristotle???Could you imagine finding out a false negative and than later finding out you missed it and are now in stage 3 or 4 or a false positive the anxiety that would cause.
Nice try with your post Olteanu007, come back in 4-5 years. These bashers have no happiness in their lives. Misinformation and negativity. It;'s just sad.
brad129 wrote: did you notice they omit percent of false negatives.
Olteanu007 wrote: Your data was from September,2020. As of right now look at what they stand: An earlier version of Galleri demonstrated the ability to detect more than 50 types of cancers over 45 of which lack recommended screening tests today in the U.S. with a low false positive rate of less than 1%. When a cancer is detected, Galleri localizes the cancer signal with high accuracy, all from a single blood draw.
ScienceFirst wrote: It always amazes me how these bashers come ill-prepared!
It interesting that Olteanu007 is trying to scare us, by omitting the most important information, when it comes to Grail.
So lets post it, to educate Olteanu007. Looks like "
high sensitivity" doesn't have the same definition, depending on who you compare against!
GRAIL’s New Blood-Based Cancer Screening Test Shows High Sensitivity and Specificity
The overall specificity was 99.4%, meaning only 0.6% of the results incorrectly indicated that cancer was present. The sensitivity of the assay for detecting a pre-specified high mortality cancer (the percent of blood samples from these patients that tested positive for cancer) was 76%. Within this group, the sensitivity was 32% for patients with stage I cancer; 76% for those with stage II; 85% for stage III; and 93% for stage IV. Sensitivity across all cancer types was 55%, with similar increases in detection by stage. For the 97% of samples that returned a tissue of origin result, the test correctly identified the organ or tissue of origin in 89% of cases.